Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 10, 2011, Pages 1798-1805

  Oh, So Won ^a   Moon, Seung Hwan ^a   Park, Do Joon ^a   Cho, Bo Youn ^a   Jung, Kyeong Cheon ^a   Lee, Dong Soo ^a,b   Chung, June Key ^a  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

131I therapy; Refractory papillary thyroid cancer; Retinoic acid

Indexed keywords

IODINE 131; ISOTRETINOIN; RADIOACTIVE IODINE; RETINOIC ACID; THYROGLOBULIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG UPTAKE; FEMALE; HUMAN; MALE; METASTASIS; PAPILLARY CARCINOMA; PAPILLARY THYROID CANCER; PREDICTION; RADIATION DOSE; SINGLE DRUG DOSE; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RETROSPECTIVE STUDY; SOUTH KOREA; THYROID TUMOR; TREATMENT FAILURE;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TREATMENT FAILURE; TRETINOIN;

EID: 80455174021     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1849-2     Document Type: Article

References (31)

1. Goretzki PE, Simon D, Frilling A, et al. Surgical intervention for differentiated thyroid carcinoma. Br J Surg. 1994;80:1009-12.
2. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999;141:443-57.
3. Chung JK, Youn HW, Kang JH, Lee HY, Kang KW. Sodium iodide symporter and radioiodine treatment of thyroid carcinoma. Nucl Med Mol Imaging. 2010;44:4-14.
4. Hansen LA, Sigman CC, Andreola F, Rose SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 2000;21:1271-9. (Pubitemid 30455984)
5. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer. 2001;1:181-93. (Pubitemid 33741893)
6. Fenaux P, Chomienne C, Degos L. Treatment of acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2001;14:153-74. (Pubitemid 32372404)
7. Schmutzler C, Winzer R, Meissner-Weigl J, Köhrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun. 1997;240:832-8. (Pubitemid 28271806)
8. Lee YJ, Chung JK, Shin JH, Kang JH, Jeong JM, Lee DS. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid. 2004;14:889-95.
9. Venkataraman GM, Yatin M, Marcinek R, Ain KB. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab. 1999;84:2249-57.
10. Kurebayashi J, Tanaka K, Otsuki T, et al. All-trans retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metabol. 2000;85:2889-96. (Pubitemid 32269169)
11. Simon D, Koehrle J, Reiners C, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg. 1998;22:569-74. (Pubitemid 28215434)
12. Grünwald F, Menzel C, Bender H, et al. Redifferentiation therapyinduced radioiodine uptake in thyroid cancer. J Nucl Med. 1998;39:1903-19.
13. Grünwald F, Pakos E, Bender H, et al. Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J Nucl Med. 1998;39:1555-8. (Pubitemid 28459886)
14. Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002;240:832-8.
15. Fernández CA, Puig-Domingo M, Lomeña F, et al. Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J Endocrinol Invest. 2009;32:228-33.
16. Simon D, Körber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer - final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002;29:775-82.
17. Grünig T, Tiepolt C, Zoephel K, Bredow J, Kropp J, Franke WG. Retinoic acid for redifferentiation of thyroid cancer - does it hold its promise? Eur J Nucl Med Mol Imaging. 2003;148:395-402. (Pubitemid 36527410)
18. Courbon F, Zerdoud S, Bastie D, et al. Defective efficacy of retinoid acid treatment in patients with metastatic thyroid carcinoma. Thyroid. 2006;16:1025-31. (Pubitemid 46141305)
19. Lee JJ, Chung JK, Kim SE, et al. Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2008;22:727-34.
20. Chung JK, Lee YJ, Jeong JM, et al. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma. J Nucl Med. 1997;38:1191-5. (Pubitemid 27332610)
21. Chung JK, Park YJ, Kim TY, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf). 2002;57:215-21. (Pubitemid 34989098)
22. Padhani AR, Ollivier L. The RECIST criteria: implications for diagnostic radiologists. Br J Radiol. 2001;74:983-6. (Pubitemid 33121128)
23. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours. World Health Organization: International histological classification of tumours. 2nd ed. Berlin: Springer Verlag; 1988.
24. Ahn HY, Park YJ. Incidence and clinical characteristics of thyroid cancer in Korea. Korean J Med. 2009;77:537-42.
25. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4701-4.
26. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675-84.
27. Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1:162-9.
28. Teixeira C, Pratt MA. CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells. Mol Endocrinol. 1997;11:1191-202. (Pubitemid 28041327)
29. Nagy L, Thomazy VA, Heyman RA, Davies PJ. Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ. 1998;1998:11-9. (Pubitemid 28359078)
30. Larson RS, Tallman MS. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol. 2003;16:453-61.
31. Schlumberger M, Mancusi F, Baudin E, Pacini F. 131I therapy for elevated thyroglobulin levels. Thyroid. 1997;7:273-6. (Pubitemid 27190595)